このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Jubilant Pharmova マネジメント

マネジメント基準チェック /14

Jubilant Pharmova'sの CEO はPriyavrat Bhartiaで、 Jun2023年に任命され、の在任期間は 7.08年です。は、会社の株式の0.88%を直接所有しており、その価値は₹ 1.03B 。経営陣と取締役会の平均在任期間はそれぞれ1.4年と6.4年です。

主要情報

Priyavrat Bhartia

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.9%
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	6.4yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Priyavrat Bhartia (48 yo)

less than a year

在職期間

Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Arvind Chokhany	Group CFO & Whole-Time Director	1.1yrs	₹53.43m	データなし
Laxshmivarahan Ramasubramani	Group Chief Digital & Information Officer	no data	₹16.53m	データなし
Naresh Kapoor	Company Secretary & Compliance Officer	1.8yrs	₹6.86m	データなし
Praveen Gupta	Executive VP & Head of Direct Taxation	no data	₹21.06m	データなし
K.V.S Kumar	Chief Sustainability Officer	no data	₹16.73m	データなし
Priyavrat Bhartia	MD & Director	less than a year	データなし	0.88% ₹ 1.0b
Arjun Bhartia	Joint MD & Director	less than a year	データなし	データなし
Prakash Bisht	Executive VP of Group Accounts	no data	データなし	データなし
Surajit Pal	Head of Investor Relations	no data	データなし	データなし
Sanjay Gupta	Executive VP & Head of Legal	9.6yrs	₹3.34m	データなし
Shantanu Jha	Group Chief Human Resources Officer	1.4yrs	データなし	データなし
Rajagopal Sankaraiah	Advisor	4.3yrs	₹67.29m	データなし

1.4yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: 530019の経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Arvind Chokhany	Group CFO & Whole-Time Director	3.2yrs	₹53.43m	データなし
Priyavrat Bhartia	MD & Director	7.1yrs	データなし	0.88% ₹ 1.0b
Arjun Bhartia	Joint MD & Director	7.1yrs	データなし	データなし
Arul Ramakrishan	Additional Director & Whole-time Director	no data	データなし	データなし
Shyam Sunder Bhartia	Chairman	46yrs	データなし	0.084% ₹ 99.2m
Sushil Roongta	Independent Non-Executive Director	7.1yrs	₹1.76m	データなし
Arun Seth	Independent Non-Executive Director	5.7yrs	₹1.38m	0.0013% ₹ 1.5m
Harsh Mahajan	Independent Director	less than a year	データなし	データなし
Hari Bhartia	Co-Chairman	40.6yrs	₹119.90m	0.23% ₹ 274.3m
Shivpriya Nanda	Independent Director	less than a year	データなし	データなし
Vivek Mehra	Independent Non-Executive Director	7.1yrs	₹1.85m	データなし
Shirish Belapure	Additional Independent Non-Executive Director	1.3yrs	データなし	データなし

6.4yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: 530019の取締役会は経験豊富であると考えられます ( 6.4年の平均在任期間)。

Jubilant Pharmova マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

Recent updates

Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024

Full year 2024 earnings released: EPS: ₹4.84 (vs ₹3.83 loss in FY 2023)

Jubilant Pharmova Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Third quarter 2024 earnings released: EPS: ₹4.22 (vs ₹0.98 loss in 3Q 2023)

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Second quarter 2024 earnings released: EPS: ₹3.94 (vs ₹0.34 in 2Q 2023)

Price target decreased by 8.9% to ₹395

Jubilant Pharmova Limited to Report Fiscal Year 2024 Results on May 17, 2024

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹0.40 (vs ₹2.96 in 1Q 2023)

Jubilant Pharmova Limited to Report Fiscal Year 2023 Results on Jul 19, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Full year 2023 earnings released: ₹3.83 loss per share (vs ₹26.01 profit in FY 2022)

Jubilant Pharmova Limited to Report Q4, 2023 Results on May 29, 2023

Now 21% undervalued after recent price drop

Price target decreased by 11% to ₹384

Third quarter 2023 earnings released: ₹0.98 loss per share (vs ₹3.20 profit in 3Q 2022)

Jubilant Pharmova Limited to Report Q3, 2023 Results on Feb 03, 2023

Price target decreased to ₹391

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited to Report Q2, 2023 Results on Oct 21, 2022

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Price target decreased to ₹434

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before October 24, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

Consensus forecasts updated

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹2.96 (vs ₹10.09 in 1Q 2022)

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited to Report Q1, 2023 Results on Aug 02, 2022

High number of new directors

Price target decreased to ₹507

Jubilant Pharmova Limited Approves Executive and Board Changes

Consensus EPS estimates fall by 18%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before September 7, 2022

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to ₹711

Second quarter 2022 earnings released: EPS ₹8.97 (vs ₹14.06 in 2Q 2021)

Price target decreased to ₹802

Price target decreased to ₹869

First quarter 2022 earnings released: EPS ₹10.09 (vs ₹5.53 in 1Q 2021)

Jubilant Pharmova Announces That the US FDA Has Placed Roorkee Facility Under Import Alert

Consensus revenue estimates fall to ₹65.7b

Full year 2021 earnings released: EPS ₹36.05 (vs ₹56.40 in FY 2020)

New 90-day low: ₹752

Price target raised to ₹1,021

Analysts update estimates

President of Manufacturing & Whole-Time Director Anant Pande has left the company

CEO of Life Science Ingredients & Whole-Time Director Rajesh Srivastava has left the company

Jubilant Pharmova Limited Announces Directorate Changes

Third quarter 2021 earnings released: EPS ₹13.75 (vs ₹12.77 in 3Q 2020)

Earnings beat expectations, revenue disappoints

New 90-day high: ₹1,026

Jubilant Life Sciences Limited to Report Q3, 2021 Results on Feb 05, 2021

New 90-day high: ₹978

New 90-day high: ₹866

Market bids up stock over the past week

New 90-day high: ₹820

New 90-day low: ₹683

Revenue and earnings miss expectations

Second quarter 2021 earnings released: EPS ₹14.06

Jubilant Life Sciences Limited to Report Q2, 2021 Results on Nov 04, 2020

Independent Non-Executive Director recently bought ₹1.1m worth of stock

Analysts lower EPS estimates to ₹55.56

マネジメント基準チェック /14